Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8222920 | 0.80 | DDB1 (0.40) | HRH4ALDH1A1KMT2AL3MBTL1MAPT | |
| SCHEMBL28076318 | 0.79 | GAA (0.55) | ALDH1A1GAAKMT2ASLC6A2SLC6A4 | |
| SCHEMBL2840431 | 0.77 | SLC6A2 (0.36) | HRH4ALDH1A1GAAKMT2ASLC6A2 | |
| SCHEMBL24316006 | 0.76 | PSEN1 (0.49) | ALDH1A1KMT2AL3MBTL1MAPTHTT | |
| SCHEMBL22819191 | 0.74 | CYP19A1 (0.43) | ALDH1A1GAAKMT2ASLC6A2SLC6A4 | |
| SCHEMBL2852394 | 0.74 | SLC6A2 (0.37) | HRH4ALDH1A1GAAKMT2ASLC6A2 | |
| SCHEMBL13566136 | 0.72 | PSEN1 (0.41) | KMT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23278085 | 0.71 | CHEK1 (0.42) | ALDH1A1SLC6A2SLC6A4L3MBTL1MAPT | |
| SCHEMBL2850957 | 0.70 | SLC6A2 (0.35) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1136123 | 0.70 | ATM (0.47) | ALDH1A1L3MBTL1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304461-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-10-20 | — | — | US | disclosed |
| US-9403773-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150218101-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | US | disclosed |
| US-9045464-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140121207-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-8642619-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-04 | — | — | US | disclosed |
| US-20120316168-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-5929072-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1999-07-27 | — | — | US | disclosed |
| WO-1999010346-A1 | BENZOTHIADIAZINYL-INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR LIGANDS | ELI LILLY AND COMPANY LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
| EP-0897921-A1 | Benzothiadiazinyl-indole derivatives and their use as serotonin receptor ligands | ELI LILLY AND COMPANY LIMITED (GB) | 1999-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316168-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | HRH4 342/4885ALDH1A1 692/4885GAA 2164/4885 |
| US-20140121207-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | HRH4 342/4885ALDH1A1 692/4885GAA 2164/4885 |
| US-20160304461-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | HRH4 342/4885ALDH1A1 692/4885GAA 2164/4885 |
| US-20150218101-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | HRH4 342/4885ALDH1A1 692/4885GAA 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.